Market Overview

Cambrex Reports Second Quarter 2018 Financial Results

Share:

- Net Revenue increased 13% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 -

- 2018 full year Adjusted Net Revenue Growth and Adjusted EBITDA guidance reaffirmed -

- Agreement to acquire Halo Pharma, broadening capabilities, enhancing revenue growth and expanding customer base -

- Conference call at 8:30 a.m. ET on August 2, 2018 -

EAST RUTHERFORD, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the second quarter ended June 30, 2018.

Highlights

  • Net revenue increased 13% to $152.0 million compared to $134.6 million in the same quarter last year.  Excluding the impact of adopting the new revenue standard, ASC 606 – Revenue from Contracts with Customers, net revenue decreased 1%.

  • GAAP Diluted EPS from continuing operations increased 61% to $1.21 per share from $0.75 per share in the same quarter last year.  The 2018 results reflect a lower tax rate as a result of tax reform in the United States. Excluding the impact of adopting ASC 606, Diluted EPS from continuing operations was $0.87 per share.

  • EBITDA increased 22% to $52.2 million compared to $42.6 million in the same quarter last year. Adjusted EBITDA, which excludes the impact of adopting ASC 606, decreased to $37.2 million from $42.6 million in the same quarter last year (see table at the end of this release).

  • Net cash was $171.3 million at the end of the quarter, a decrease of $16.2 million during the quarter.

  • The Company continues to expect full year 2018 Adjusted net revenue growth, which excludes the impact of foreign currency and adoption of ASC 606, to be between -2% and 2% compared to 2017 and Adjusted EBITDA to be between $150 and $160 million. This does not include the impact of the Halo acquisition (see Financial Expectations – Continuing Operations section below for related explanations and additional financial guidance).

  • Entered into a definitive agreement to acquire Halo Pharma, a leading dosage form Contract Development and Manufacturing Organization (CDMO) specializing in product development and commercial manufacturing, for approximately $425 million in total cash consideration.

"Our recent accomplishments mark significant progress toward our goals of investing in increased capacity and expanding our capabilities in order to take advantage of favorable industry trends and provide best-in-class services for our global customers. Most notably, we were pleased to announce the agreement to acquire Halo Pharma, which expands our offerings into finished dose development and manufacturing, while diversifying our customer base and accelerating our revenue growth," commented Steven M. Klosk, President and Chief Executive Officer.

"We are also encouraged by second quarter performance across our three product categories. We recently added a new late-stage clinical project to our innovator portfolio with the potential to generate between $5 million and $10 million in peak API sales. This brings the total to three new late-stage projects added during the first half of 2018, with the combined potential to generate greater than $25 million in API revenue. Sales of generic APIs and controlled substances were also strong in the quarter."

Basis of Reporting

The Company has provided a reconciliation of GAAP to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Cambrex management believes that the adjustments provide useful information to investors due to the magnitude and nature of certain amounts recorded under GAAP.

Second Quarter 2018 Operating Results – Continuing Operations

Net revenue was $152.0 million, an increase of $17.5 million, or 13%, compared to the second quarter of 2017. Excluding a 2% favorable impact of foreign exchange compared to the second quarter of 2017, net revenue increased 11%. The increase in volumes is driven by higher custom development products, generic APIs and the adoption of ASC 606, which accelerated revenue recognition for a portion of Cambrex's portfolio, enabling revenues for certain products to be recognized over time, rather than upon delivery to the customer.  Cambrex elected the modified retrospective method which did not require prior periods to be restated. The increases were partially offset by lower pricing. Excluding the impact of adopting ASC 606, net revenue decreased 1%.  
           
Gross margins were flat at 43% versus the same quarter last year. Excluding the impact of adopting ASC 606, gross margin was 37%.

Selling, general and administrative expenses were $16.0 million, compared to $18.1 million in the same quarter last year.  This decrease was primarily due to lower personnel related costs.

Research and development expenses were $4.1 million, compared to $4.5 million in the same quarter last year. This decrease was primarily driven by the timing of spending on the development of generic drug products.

Operating profit was $44.7 million compared to $35.0 million in the same quarter last year.  The increase was primarily the result of higher gross profit and lower operating expenses as described above.  Excluding the impact of adopting ASC 606, operating profit was $29.7 million.  Adjusted EBITDA was $37.2 million compared to $42.6 million in the same quarter last year (see table at the end of this press release). 
           
Income tax expense was $8.7 million resulting in an effective tax rate of 18% compared to $9.2 million and an effective tax rate of 27% in the same quarter last year.  The reduction in the effective tax rate reflects the impact of tax reform in the United States.

Income from continuing operations was $40.9 million or $1.21 per share compared to $25.1 million or $0.75 per share in the same quarter last year. Excluding the impact of adopting ASC 606, Diluted EPS from continuing operations was $0.87 per share.

Adjusted income from continuing operations was $24.7 million or $0.74 per share, compared to $25.4 million or $0.76 per share in the same quarter last year (see table at the end of this press release).

Capital expenditures were $8.9 million and depreciation and amortization was $7.5 million compared to $10.7 million and $7.6 million, respectively, in the same quarter last year.

Net cash was $171.3 million at the end of the second quarter, a decrease of $16.2 million during the quarter.

Financial Expectations – Continuing Operations

The following table shows the Company's current expectations for its full year 2018 financial performance versus its expectations from the previous quarter. These expectations do not reflect the impact of the acquisition of Halo Pharma on 2018 results. The Company expects to issue revised guidance in our third quarter call once the acquisition has closed.

    Current Expectations   Previous Expectations
         
Adjusted net revenue growth   -2% - 2%   -2% - 2%
         
Adjusted EBITDA   $150 - $160 million   $150 - $160 million
         
Adjusted income from continuing operations per share   $2.91 - $3.14   $2.80 - $3.03
         
Free cash flow   $35 - $45 million   $35 - $45 million
         
Capital expenditures   $70 - $80 million   $70 - $80 million
         
Depreciation and amortization   $33 - $37 million   $33 - $37 million
         
Adjusted effective tax rate   20% - 22%   23% - 25%
         

Consistent with the Company's usual guidance practices, these financial expectations are for continuing operations and exclude the impact of any potential acquisitions, divestitures, restructuring activities, outcomes of tax disputes and the adoption of ASC 606 which became effective January 1, 2018.  Adjusted net revenue growth expectations exclude the impact of foreign exchange and the adoption of ASC 606.  EBITDA, Adjusted EBITDA and Adjusted income from continuing operations per share for 2018 will be computed on a basis consistent with the reconciliation of the current quarter financial results in the tables at the end of this press release. Free cash flow is defined as the change in debt, net of cash during the year.  Adjusted effective tax rate excludes certain effects of share-based payments that were possibly deferred under the previous guidance.  The tax rate will be sensitive to the Company's geographic mix of income, changes in the tax laws or rates within the countries in which the Company operates and the effects of certain share-based payments.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's Form 10-Q for second quarter 2018 is filed with the SEC.

Conference Call and Webcast

A conference call to discuss the Company's second quarter 2018 results will begin at 8:30 a.m. Eastern Time on August 2, 2018 and can be accessed by calling 1-888-208-1711 for domestic and +1-323-794-2575 for international.  Please use the passcode 3913181 and call approximately 10 minutes prior to the start time.  A webcast will be available in the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through August 9, 2018 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international. Please use the passcode 3913181 to access the replay.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.  Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing.  For more information, please visit www.cambrex.com.

Forward-Looking Statements

This document contains "forward-looking statements," including statements or tables regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," "Highlights" and those attributed to the President and Chief Executive Officer in this document.  These and other forward-looking statements may be identified by the fact that they use words such as "guidance," "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2017 captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, the possibility that conditions to closing the Halo Pharma transaction could not be met or that the benefits from the acquisition may not be as anticipated, customer and product concentration, the Company's ability to win new customer contracts and renew existing contracts on favorable terms, significant declines in sales of products to our customers, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of its customers' products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing and/or volume of orders or shipments and the Company's ability to meet its production plan and customer delivery schedules, expected timing of completion of capacity expansions, our ability to successfully integrate acquired businesses, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the successful outcome of the Company's investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including the Forward-Looking Statement and Risk Factors sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place undue reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in the Company's SEC filings.  The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

Use of Non-GAAP Financial Measures

Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations are non-GAAP financial measures. These financial non-GAAP measures exclude the adoption of ASC 606. The Company defines EBITDA as operating profit plus depreciation and amortization expense and Adjusted EBITDA excludes the impact of any potential acquisitions and restructuring activities.  Adjusted effective tax rate excludes certain effects of share-based payments that were possibly deferred under the previous guidance. Adjusted income from continuing operations is calculated in a manner consistent with that shown in the table at the end of this press release.  Other companies may have different definitions of Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations.  Therefore, these measures may not be comparable with non-GAAP financial measures provided by other companies.  Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations should not be considered alternatives to measurements required by U.S. GAAP, such as net revenue, operating profit or net income, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations among several other metrics to assess and analyze its operational results and trends.  Cambrex also believes Adjusted net revenue, EBITDA, Adjusted EBITDA, Adjusted effective tax rate and Adjusted income from continuing operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

CAMBREX CORPORATION
Statements of Profit and Loss
For the Quarters Ended June 30, 2018 and 2017
(in thousands, except per share data)
                   
    2018     2017
        % of         % of
    Amount   Net Revenue     Amount   Net Revenue
                   
Gross Sales $   147,214         $   134,487      
  Commissions, Allowances and Rebates     192             649      
Net Sales     147,022             133,838      
                   
  Other Revenues, Net     5,024             716      
                   
Net Revenue     152,046             134,554      
                   
  Cost of Goods Sold     87,254     57.4%       76,995     57.2%
                   
Gross Profit     64,792     42.6%       57,559     42.8%
                   
Operating Expenses:                  
  Selling, General and Administrative Expenses     16,007     10.5%       18,120     13.5%
  Research and Development Expenses     4,133     2.7%       4,467      3.3%
Total Operating Expenses     20,140     13.2%       22,587     16.8%
                   
Operating Profit     44,652     29.4%       34,972     26.0%
                   
Other Expenses/(Income):                  
  Interest Expense, Net     17             388      
  Unrealized Gain on Investment in Equity Securities     (5,146 )           -       
  Other Expenses, Net     181             286      
                   
Income Before Income Taxes     49,600     32.6%       34,298     25.5%
                   
  Provision for Income Taxes     8,748             9,174      
                   
Income from Continuing Operations $   40,852     26.9%   $   25,124     18.7%
                   
Loss from Discontinued Operations, Net of Tax     (433 )           (94 )    
                   
Net Income $   40,419     26.6%   $   25,030     18.6%
                   
Basic Earnings/(Loss) per Share of Common Stock:                  
  Income from Continuing Operations $   1.23         $   0.77      
  Loss from Discontinued Operations, Net of Tax $   (0.01 )       $   (0.00 )    
  Net Income $   1.22         $   0.77      
                   
Diluted Earnings/(Loss) per Share of Common Stock:                  
  Income from Continuing Operations $   1.21         $   0.75      
  Loss from Discontinued Operations, Net of Tax $   (0.01 )       $   (0.00 )    
  Net Income $   1.20         $   0.75      
                   
Weighted Average Shares Outstanding                  
  Basic     33,085             32,629      
  Diluted     33,642             33,469      
                       


CAMBREX CORPORATION
Statements of Profit and Loss
For the Six Months Ended June 30, 2018 and 2017
(in thousands, except per share data)
                   
    2018     2017
        % of         % of
    Amount   Net Revenue     Amount   Net Revenue
                   
Gross Sales $   286,344          $   238,198      
  Commissions, Allowances and Rebates     401             1,243      
Net Sales     285,943             236,955      
                   
  Other Revenues, Net     7,200             2,605      
                   
Net Revenue     293,143             239,560      
                   
  Cost of Goods Sold     177,496     60.5%       135,126     56.4%
                   
Gross Profit     115,647     39.5%       104,434     43.6%
                   
Operating Expenses:                  
  Selling, General and Administrative Expenses     32,862     11.2%       33,511     14.0%
  Research and Development Expenses     7,752      2.6%       8,357      3.5%
Total Operating Expenses     40,614     13.9%       41,868     17.5%
                   
Operating Profit     75,033     25.6%       62,566     26.1%
                   
Other Expenses/(Income):                  
  Interest Expense, Net     99             654      
  Unrealized Gain on Investment in Equity Securities     (5,146 )           -       
  Other Expenses, Net     445             687      
                   
Income Before Income Taxes     79,635     27.2%       61,225     25.6%
                   
  Provision for Income Taxes     14,534             14,986      
                   
Income from Continuing Operations $   65,101     22.2%   $   46,239     19.3%
                   
Loss from Discontinued Operations, Net of Tax     (624 )           (1,344 )    
                   
Net Income $   64,477     22.0%   $   44,895     18.7%
                   
Basic Earnings/(Loss) per Share of Common Stock:                  
  Income from Continuing Operations $   1.97         $   1.42      
  Loss from Discontinued Operations, Net of Tax $   (0.02 )       $   (0.04 )    
  Net Income $   1.95         $   1.38      
                   
Diluted Earnings/(Loss) per Share of Common Stock:                  
  Income from Continuing Operations $   1.94         $   1.38      
  Loss from Discontinued Operations, Net of Tax $   (0.02 )       $   (0.04 )    
  Net Income $   1.92         $   1.34      
                   
Weighted Average Shares Outstanding                  
  Basic     32,990             32,542      
  Diluted     33,618             33,416      
                       


CAMBREX CORPORATION
Consolidated Balance Sheets
As of June 30, 2018 and December 31, 2017
(in thousands)
           
           
    June 30,     December 31,
Assets   2018     2017
           
Cash and Cash Equivalents $ 171,348   $ 183,284
Trade Receivables, Net   100,224     75,144
Contract Assets   107,083     -
Other Receivables   15,417     20,891
Inventories, Net   99,562     138,542
Prepaid Expenses and Other Current Assets   10,589     4,217
  Total Current Assets   504,223     422,078
           
Property, Plant and Equipment, Net   266,075     254,299
Goodwill   42,864     43,626
Intangible Assets, Net   12,753     13,868
Deferred Income Taxes   1,448     3,198
Other Non-Current Assets   3,532     3,496
           
  Total Assets $ 830,895   $ 740,565
           
Liabilities and Stockholders' Equity          
           
Accounts Payable $ 51,596   $ 35,017
Contract Liabilities, Current   8,153     4,707
Taxes Payable   3,388     43
Accrued Expenses and Other Current Liabilities   33,304     42,774
  Total Current Liabilities   96,441     82,541
           
Contract Liabilities, Non-Current   39,000     39,000
Deferred Income Taxes   9,377     7,806
Accrued Pension Benefits   38,444     41,141
Other Non-Current Liabilities   24,306     25,213
           
  Total Liabilities $ 207,568   $ 195,701
           
  Stockholders' Equity $ 623,327   $ 544,864
           
  Total Liabilities and Stockholders' Equity $ 830,895   $ 740,565
           


CAMBREX CORPORATION
Impact of Adopting ASC 606
For the Three and Six Months Ended June 30, 2018 and 2017
(in thousands)
                 
                 
Income Statement    
    Second Quarter 2018   Second Quarter 2017
    As Reported   Effect of Change   Amount Without Adoption of ASC 606   As Reported
                 
Gross Sales   $   147,214   $   18,988     $   128,226     $   134,487
Net Revenue       152,046       18,988         133,058         134,554
Cost of Goods Sold       87,254       4,020         83,234         76,995
Gross Profit       64,792       14,968         49,824         57,559
Operating Profit       44,652       14,968         29,684         34,972
Provision for Income Taxes       8,748       3,463         5,285         9,174
Income from Continuing
 Operations
      40,852       11,505         29,347         25,124
Net Income       40,419       11,505         28,914         25,030
Diluted Earnings per Share       1.21       0.34         0.87         0.75
                 
                 
                 
    Six Months 2018   Six Months 2017
    As Reported   Effect of Change   Amount Without Adoption of ASC 606   As Reported
                 
Gross Sales   $   286,344   $   56,268     $   230,076     $   238,198
Net Revenue       293,143       56,268         236,875         239,560
Cost of Goods Sold       177,496       24,719         152,777         135,126
Gross Profit       115,647       31,549         84,098         104,434
Operating Profit       75,033       31,549         43,484         62,566
Provision for Income Taxes       14,534       6,634         7,900         14,986
Income from Continuing
 Operations
      65,101       24,915         40,186         46,239
Net Income       64,477       24,915         39,562         44,895
Diluted Earnings per Share       1.94       0.74         1.20         1.38
                 
                 
                 
Balance Sheet                
    June 30, 2018   December 31, 2017
    As Reported   Effect of Change   Balances Without Adoption of ASC 606   As Reported
                 
Current Assets                
Contract Assets   $   107,083   $   107,083     $   -      $   - 
Inventory       99,562       (55,129 )       154,691         138,542
                 
Current Liabilities                
Taxes Payable       3,388       10,964         (7,576 )       43
                             
Stockholders' Equity                            
Retained Earnings     510,522     41,134       469,388       429,826
                             


CAMBREX CORPORATION
Reconciliation of GAAP to non-GAAP Results
For the Three and Six Months Ended June 30, 2018 and 2017
(in thousands)
             
  Second Quarter 2018     Second Quarter 2017
             
Operating Profit $ 44,652     $ 34,972
             
Depreciation and Amortization     7,502       7,642
             
EBITDA     52,154       42,614
             
Impact of Adopting ASC 606     (14,968 )     -
             
Adjusted EBITDA $   37,186     $ 42,614
             
 
  Six Months 2018     Six Months 2017
             
Operating Profit $ 75,033     $ 62,566
             
Depreciation and Amortization     15,019       14,827
             
EBITDA     90,052       77,393
             
Impact of Adopting ASC 606     (31,549 )     -
             
Adjusted EBITDA $   58,503     $ 77,393
             


CAMBREX CORPORATION
Reconciliation of GAAP to non-GAAP Results
For the Three and Six Months Ended June 30, 2018 and 2017
(in thousands)
                         
        Second Quarter 2018   Second Quarter 2017
              Diluted EPS         Diluted EPS
Income from Continuing Operations   $   40,852   $   1.21     $   25,124   $   0.75  
                         
Impact of Adopting ASC 606       (11,505 )     (0.34 )       -        -   
Stock-Based Compensation       1,553       0.05         2,247       0.07  
Stock-Based Compensation Tax 1.       (1,533 )     (0.05 )       (2,512 )     (0.08 )
Amortization of Purchased Intangibles     510       0.02         500       0.01  
Unrealized Gain on Investment in Equity Securities   (5,146 )     (0.15 )       -        -   
                         
Adjusted Income from Continuing Operations 2. $   24,731   $   0.74     $   25,359   $   0.76  
                         
                         
        Six Months 2018   Six Months 2017
              Diluted EPS         Diluted EPS
Income from Continuing Operations   $   65,101   $   1.94     $   46,239   $   1.38  
                         
Impact of Adopting ASC 606       (24,915 )     (0.74 )       -        -   
Stock-Based Compensation       3,203       0.10         4,033       0.12  
Stock-Based Compensation Tax 1.       (1,998 )     (0.06 )       (5,791 )     (0.17 )
Amortization of Purchased Intangibles     1,023       0.03         898       0.03  
Unrealized Gain on Investment in Equity Securities   (5,146 )     (0.15 )       -        -   
                         
Adjusted Income from Continuing Operations 2. $   37,268   $   1.11     $   45,379   $   1.36  
                           

1.   Amount represents the tax effect for non-cash stock-based compensation expense and the immediate recognition of certain effects of share-based payments.
2.   Diluted earnings per share for adjusted income from continuing operations is based on the weighted number of diluted shares outstanding for the quarter and year. As such, the sum of the quarters may not necessarily equal the full year. In addition, the sum of the line items may not equal due to rounding.

Contact:       Tom Vadaketh
Executive Vice President & CFO
Tel: +201.804.3033
Email: tom.vadaketh@cambrex.com
     

Primary Logo

View Comments and Join the Discussion!